Last reviewed · How we verify
Allergovac himenoptera — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Allergovac himenoptera (Allergovac himenoptera) — Roxall Medicina España S.A. Allergen immunotherapy that induces immune tolerance to hymenoptera venom through gradual exposure to increasing doses of venom allergens.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allergovac himenoptera TARGET | Allergovac himenoptera | Roxall Medicina España S.A | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allergovac himenoptera CI watch — RSS
- Allergovac himenoptera CI watch — Atom
- Allergovac himenoptera CI watch — JSON
- Allergovac himenoptera alone — RSS
Cite this brief
Drug Landscape (2026). Allergovac himenoptera — Competitive Intelligence Brief. https://druglandscape.com/ci/allergovac-himenoptera. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing